ACPM recommends…
July 5, 2010
THE Advisory Committee on
Prescription Medicines (ACPM) has
recommended that the TGA
approve Servier Laboratories’ new
chemical entity, agomelatine
(Valdoxan), in 25mg coated tablet
dosages for the treatment of major
depression, and relapse prevention.
The ACPM has also
recommended that the TGA
approve Janssen-Cilag’s application
to register a new salt of a previously
approved active, paliperidone
palmitate (Invega Sustenna), as a
modified release aqueous solution
for 25mg, 50mg, 75mg, 100mg
and 150mg injection for the
treatment and maintenance of
schizophrenia in adults.
The above article was sent to subscribers in Pharmacy Daily's issue from 05 Jul 10To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 05 Jul 10